University Hospital Würzburg, 97080, Würzburg, Germany.
Sydney School of Public Health, The University of Sydney Centre for Kidney Research, The Children's Hospital at Westmead, Camperdown, Australia.
Syst Rev. 2024 Nov 14;13(1):280. doi: 10.1186/s13643-024-02672-4.
Patients with kidney failure often lack robust evidence because they are excluded from randomized trials. Trial emulation provides an alternative approach to derive treatment effect estimates when randomized trials cannot be conducted. Critical questions about the comparative efficacy and safety of interventions in kidney failure are now being answered using this approach or parts of it. However, variations and inconsistencies in reporting cast doubt on the reliability and validity of effect estimates not derived from randomized trials. The aim of this methodological systematic review is to understand the extent to which the target study approach is used in kidney failure and the appropriateness of this approach. By identifying and evaluating studies that qualify as emulating a target trial, compared with studies that did not apply the principles. We aim to provide more specific methodological guidance to increase the clarity and reliability of reporting treatment effect estimates when running a trial in kidney failure is not feasible.
This protocol is developed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) statement. MEDLINE, Embase, and reference lists (backwards citation chasing) will be searched up until 1st July 2023 and the search updated prior to publication to identify all studies evaluating patient outcomes in late-stage kidney disease and failure that use target trial emulation as the primary approach for analysis. Two authors (A. A., P. K.) will select articles based on title and abstract and then full text, with a third reviewer settling disagreements (J. P.). The prespecified variables will be extracted, and the risk of bias will be assessed by at least two authors (A. A., P. K., A. N.) using prespecified data forms. This will enable the determination of the robustness of the methodological quality of observational studies in using the whole or elements of the target trial approach. We will thereby assess their ability to reliably report treatment effect estimates.
We will provide specific methodological recommendations on how to design target trials and model assumptions for emulation to get reliable treatment effect estimates for therapeutic interventions in kidney failure.
Open Science Framework: Identifier https://doi.org/10.17605/OSF.IO/Z4Y29 .
肾衰竭患者常因被排除在随机试验之外而缺乏有力的证据。试验模拟为无法进行随机试验时提供了一种替代方法来获得治疗效果估计。目前,使用这种方法或其部分内容来回答关于肾衰竭中干预措施的比较疗效和安全性的关键问题。然而,报告中的差异和不一致性令人怀疑非随机试验得出的效果估计的可靠性和有效性。本方法学系统评价的目的是了解目标研究方法在肾衰竭中的应用程度以及该方法的适当性。通过识别和评估符合模拟目标试验的研究,与未应用这些原则的研究进行比较。我们旨在提供更具体的方法学指导,以提高在肾衰竭中进行试验不可行时报告治疗效果估计的清晰度和可靠性。
本方案是根据系统评价和荟萃分析报告的首选条目(PRISMA-P)声明制定的。截至 2023 年 7 月 1 日,将通过 MEDLINE、Embase 和参考文献列表(回溯引文追踪)进行搜索,并在发布前更新搜索,以确定所有评估晚期肾脏疾病和衰竭患者结局并将目标试验模拟作为主要分析方法的研究。两位作者(A. A.、P. K.)将根据标题和摘要选择文章,然后是全文,由第三位审稿人解决分歧(J. P.)。将提取预设变量,并使用预设数据表格由至少两位作者(A. A.、P. K.、A. N.)评估偏倚风险。这将能够确定使用目标试验方法的整体或部分的观察性研究的方法学质量的稳健性。从而评估它们可靠报告治疗效果估计的能力。
我们将提供具体的方法学建议,说明如何设计目标试验和模拟假设,以获得肾衰竭中治疗干预的可靠治疗效果估计。
开放科学框架:标识符 https://doi.org/10.17605/OSF.IO/Z4Y29。